U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07162324) titled 'A Multicenter, Prospective Study for Glioblastoma Patients' on Aug. 06.
Brief Summary: Glioblastoma (GBM) is the most common and aggressive primary tumor of the adult central nervous system (CNS), with a poor prognosis and median overall survival ranging between 14 to 20 months despite advancements in diagnostic and therapeutic strategies. This prospective, observational, multicenter study aims to collect and analyze comprehensive data from GBM patients treated across selected centers in Europe and the United States, the investigators' centers included. Information will include demographics, imaging findings, molecular subtypes, cl...